查詢結果分析
來源資料
相關文獻
- Benefit of Postoperative Multimodality Therapy in Patients with Locally Advanced Esophageal Cancer
- Concurrent Chemoradiation with Weekly Cisplatin Plus Systemic Adjuvant Chemotherapy for Locally Advanced Esophageal Cancer--A Pilot Study
- Surgery Followed by Concurrent Chemoradiation with Weekly Cisplatin and Adjuvant Systemic Chemotherapy for Locally Advanced Esophageal Cancer--A Piolot Study
- p53 Gene Alternation in Squamous Cell Carcinoma of the Esophagus Detected by PCR-Cold SSCP Analysis
- Clinical Application of Ultrasonic Mini-Probes in Esophageal Cancer: The Experience of Ntuh
- Bronchial Recurrence after Resection of Carcinoma of the Esophagus
- 食道癌之化學放射治療
- 檳榔與食道癌
- Synchronous Double Cancers of Intraepithelial Esophageal Squamous Cell Carcinoma and Small Hepatocellular Carcinoma in a Patient with B Hepatitis and Alcoholism: Report of a Case
- 一位食道癌末期個案之護理經驗
頁籤選單縮合
題 名 | Benefit of Postoperative Multimodality Therapy in Patients with Locally Advanced Esophageal Cancer=術後多重輔助治療對於進展性食道癌治療之好處 |
---|---|
作 者 | 洪世凱; 許文林; 張國華; 劉洪彰; 劉岱瑋; 夏錫生; 陳裕仁; 李文星; | 書刊名 | 慈濟醫學 |
卷 期 | 17:5 民94.10 |
頁 次 | 頁311-317+382 |
分類號 | 416.216 |
關鍵詞 | 食道癌; 同步化學放射線治療; 每週cisplatin; 多重整合治療; Esophageal cancer; Concurrent chemoradiotherapy; Weekly cisplatin; Multimodality therapy; |
語 文 | 英文(English) |
中文摘要 | 目的:評估術後多重輔助治療對於進展性食道癌治療結果的療效及毒性。病人與方法:從2000年6月到2004年12月共有60位術後局部進展性的病人符合T3-4及N0或N1的條件。經過手術之後,其中30位病人接受同步化學放射線治療及全身性的化學治療,其餘30位病人只單獨接受放射線治療。放射線治療對於兩組的設計劑量相同,為55-60 Gy。同步化學治療為每週一次低劑量的cisplatin(30 mg/m²),共6次。間隔3到4週後,給予全身性的化學治療。設計劑量為每月一次,每次cisplatin(20 mg/m²)加5-FU(1000 mg/m²)D1-D5,共4次。結果:治療結果在這兩個組別對於中值存活(20.5 months vs 10 months)及3年存活率(66.7% vs 29.6%, p=0.02)有明顯差異。腫瘤組織型態(moderate-well differentiation)及大小(tumor size ≤ 4.3 cm)為影響存活的因子。對於副作用的發生及耐受度是可以接受的。結論:在這個研究設計之下,術後週期性及低劑量的同步化學放射線治療合併全身性的化學治療,對於局部進展性的食道癌,不但在副作用上是可以接受的,而且在存活率及局部控制上可能是有幫助的。 |
英文摘要 | Objective: This pilot study was conducted to evaluate the efficacy and toxicity of a three-step combination therapy for locally advanced esophageal cancer. Patients and Methods: Sixty patients with T3-4 and No-1 esophageal carcinoma from a number of institutions were retrospectively enrolled in the study. All patients underwent single-stage curative en bloc esophagectomy. All patients underwent a curative resection with a margin negative for malignant cells. The patients were then assigned into one of two treatment groups based on treatment consisting of either postoperative concurrent chemoradiotherapy (CCRT) with weekly cisplatin 30 mg/m² followed by systemic adjuvant chemotherapy (four monthly cycles of cisplatin 20 mg/m² and 5-fluorouracil 1000 mg/m² for five consecutive days), or postoperative radiation alone. The radiotherapy dose was 55-60 Gy for all patients. Study end points included survival rate, median survival, toxicity, and prognostic efficacy. Results: A total of 60 patients (n=30 per group) were enrolled in this study. The two groups were generally comparable for patient characteristics and hematological and non-hematological toxicities. The CCRT with weekly cisplatin was well tolerated, with significantly better median survival, (20.5 vs 10.0months) and three-year overall survival (66.7%) vs 29.6%, p<0.05) demonstrated for members of this treatment group compared to the radiation alone group. In the current study, low histological grading (p<0.001) and tumor size≤4.3 cm (p=0.009) were associated with favorable survival in these patients with locally advanced disease. Conclusions: for locally advanced esophageal cancer, the combination of esophagectomy, postoperative CCRT with weekly cisplatin and systemic adjuvant chemotherapy may be well tolerated and effective. A large-scale, prospective randomized trial of this regimen is being conducted. |
本系統中英文摘要資訊取自各篇刊載內容。